デフォルト表紙
市場調査レポート
商品コード
993575

In Vivo受託調査機関(CRO)の世界市場

In Vivo Contract Research Organization (CRO)

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 214 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

In Vivo受託調査機関(CRO)の世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 214 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のIn Vivo受託調査機関(CRO)の市場規模は、分析期間(2020年~2027年)に7.1%のCAGRで成長する見通しで、2020年の35億米ドルから、2027年には57億米ドルに達すると予測されています。

当レポートは、世界のIn Vivo受託調査機関(CRO)市場について調査しており、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • American Preclinical Services, LLC.
  • Charles River Laboratories
  • Covance Inc.
  • Evotec (US), Inc.
  • ICON Plc
  • inVentiv Health
  • Parexel International
  • Pharmaceutical Product Development, LLC (PPD)
  • Quintiles
  • Theorem Clinical research
  • WuXi AppTec, Inc.

目次

I. 調査手法

II. エグゼクティブサマリー

  • 市場概要
    • インフルエンサー市場の洞察
    • 世界市場の軌跡
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と成長要因
  • 世界市場の見通し

III. 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

IV. 競合

  • 企業プロファイル:34社
目次
Product Code: MCP22021

Abstract:

Global In Vivo Contract Research Organization (CRO) Market to Reach $5.7 Billion by 2027

Amid the COVID-19 crisis, the global market for In Vivo Contract Research Organization (CRO) estimated at US$3.5 Billion in the year 2020, is projected to reach a revised size of US$5.7 Billion by 2027, growing at aCAGR of 7.1% over the period 2020-2027. Rodend-based, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$5.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Rodend based segment is readjusted to a revised 5.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1 Billion, While China is Forecast to Grow at 6.6% CAGR

The In Vivo Contract Research Organization (CRO) market in the U.S. is estimated at US$1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$991.1 Million by the year 2027 trailing a CAGR of 6.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.7% and 5.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Select Competitors (Total 34 Featured) -

  • American Preclinical Services, LLC.
  • Charles River Laboratories
  • Covance Inc.
  • Evotec (US), Inc.
  • ICON Plc
  • inVentiv Health
  • Parexel International
  • Pharmaceutical Product Development, LLC (PPD)
  • Quintiles
  • Theorem Clinical research
  • WuXi AppTec, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for In Vivo Contract Research Organization (CRO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Rodend-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Rodend-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Rodend-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Non-Rodend based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Non-Rodend based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Non-Rodend based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for GLP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for GLP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for GLP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Non-GLP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Non-GLP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Non-GLP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Autoimmune / Inflammatory Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Autoimmune / Inflammatory Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Autoimmune / Inflammatory Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Pain Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 28: USA Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027
    • TABLE 31: USA Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: USA Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: USA 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027
    • TABLE 34: USA Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: USA Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: USA 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 37: Canada Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Canada Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Canada 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027
    • TABLE 40: Canada Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Canada Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Canada 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027
    • TABLE 43: Canada Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Canada Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Canada 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 46: Japan Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Japan Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Japan 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027
    • TABLE 49: Japan Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Japan Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Japan 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027
    • TABLE 52: Japan Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Japan Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Japan 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 55: China Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: China Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: China 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027
    • TABLE 58: China Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: China Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: China 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027
    • TABLE 61: China Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: China Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: China 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 64: Europe Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 65: Europe Historic Review for In Vivo Contract Research Organization (CRO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 67: Europe Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Europe Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027
    • TABLE 70: Europe Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Europe Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027
    • TABLE 73: Europe Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Europe Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 76: France Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: France Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: France 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027
    • TABLE 79: France Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: France Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: France 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027
    • TABLE 82: France Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: France Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: France 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 85: Germany Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Germany Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Germany 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027
    • TABLE 88: Germany Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Germany Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Germany 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027
    • TABLE 91: Germany Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Germany Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Germany 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 94: Italy Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Italy Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Italy 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027
    • TABLE 97: Italy Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Italy Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Italy 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027
    • TABLE 100: Italy Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Italy Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Italy 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 103: UK Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: UK Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: UK 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027
    • TABLE 106: UK Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: UK Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: UK 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027
    • TABLE 109: UK Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: UK Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: UK 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 112: Rest of Europe Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Rest of Europe Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Rest of Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027
    • TABLE 115: Rest of Europe Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Rest of Europe Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Rest of Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027
    • TABLE 118: Rest of Europe Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Rest of Europe Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: Rest of Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 121: Asia-Pacific Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Asia-Pacific Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: Asia-Pacific 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027
    • TABLE 124: Asia-Pacific Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Asia-Pacific Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: Asia-Pacific 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027
    • TABLE 127: Asia-Pacific Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Asia-Pacific Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: Asia-Pacific 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 130: Rest of World Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Rest of World Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: Rest of World 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027
    • TABLE 133: Rest of World Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Rest of World Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: Rest of World 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027
    • TABLE 136: Rest of World Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Rest of World Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: Rest of World 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 34